Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $382.5 million.

  • IDEAYA Biosciences' Non-Current Assets rose 2431.98% to $382.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 6705.38%. This contributed to the annual value of $434.4 million for FY2024, which is 27226.87% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Non-Current Assets stood at $382.5 million for Q3 2025, which was up 2431.98% from $355.7 million recorded in Q2 2025.
  • IDEAYA Biosciences' Non-Current Assets' 5-year high stood at $434.4 million during Q4 2024, with a 5-year trough of $17.5 million in Q3 2022.
  • Its 5-year average for Non-Current Assets is $164.8 million, with a median of $116.7 million in 2023.
  • As far as peak fluctuations go, IDEAYA Biosciences' Non-Current Assets surged by 124883.07% in 2021, and later tumbled by 8661.11% in 2022.
  • IDEAYA Biosciences' Non-Current Assets (Quarter) stood at $130.4 million in 2021, then plummeted by 86.56% to $17.5 million in 2022, then skyrocketed by 566.19% to $116.7 million in 2023, then skyrocketed by 272.27% to $434.4 million in 2024, then decreased by 11.95% to $382.5 million in 2025.
  • Its Non-Current Assets was $382.5 million in Q3 2025, compared to $355.7 million in Q2 2025 and $392.8 million in Q1 2025.